Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia
- PMID: 28743526
- DOI: 10.1016/j.juro.2017.07.075
Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia
Abstract
Purpose: In this retrospective cohort study we assessed the effect on prostate specific antigen concentration of low dose finasteride or dutasteride treatment for male androgenetic alopecia in men with baseline serum prostate specific antigen less than 2.5 ng/ml.
Materials and methods: The cohort consisted of 1,379 consecutive male patients who were treated for androgenetic alopecia with finasteride 1.25 mg daily or dutasteride 0.5 mg every 3 days in 2002 to 2012 and who underwent prostate specific antigen measurements at baseline and at least once thereafter. Patients in whom baseline or followup prostate specific antigen after prescription exceeded 2.5 ng/ml were excluded from study to rule out men with a higher likelihood of prostate cancer. Patients were stratified according to age, baseline prostate specific antigen, medication type and treatment duration.
Results: Overall low dose 5α-reductase inhibitor treatment reduced prostate specific antigen by 27.8% relative to baseline. Of the patients 1,094 (79.3%) showed prostate specific antigen decreases (average 40.8%). In the remaining 285 patients (20.7%) prostate specific antigen was stable or increased (average 24.2% increase). Closer analysis largely showed that only men with baseline prostate specific antigen 0.5 ng/ml or greater had a treatment related prostate specific antigen reduction. On multivariate logistic analysis low baseline prostate specific antigen was significantly associated with stable/increased prostate specific antigen. Low dose dutasteride and finasteride reduced prostate specific antigen to similar degrees (31.1% and 25.1%, respectively). A marked prostate specific antigen decrease of 26.0% was observed even after short-term treatment (3 to 6 months).
Conclusions: Dutasteride and finasteride reduced prostate specific antigen to similar degrees. This effect was observed soon after commencing treatment. In patients with low baseline prostate specific antigen the levels could remain stable or even increase. These findings are limited to men with baseline prostate specific antigen less than 2.5 ng/ml.
Keywords: 5-alpha reductase inhibitors; alopecia; dihydrotestosterone; prostate; prostate-specific antigen.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.Indian J Dermatol Venereol Leprol. 2017 Jan-Feb;83(1):47-54. doi: 10.4103/0378-6323.188652. Indian J Dermatol Venereol Leprol. 2017. PMID: 27549867 Clinical Trial.
-
Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.Acta Derm Venereol. 2019 Jan 1;99(1):12-17. doi: 10.2340/00015555-3035. Acta Derm Venereol. 2019. PMID: 30206635
-
Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.Australas J Dermatol. 2013 Feb;54(1):49-51. doi: 10.1111/j.1440-0960.2012.00909.x. Epub 2012 Jun 12. Australas J Dermatol. 2013. PMID: 22686691
-
The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.Clin Interv Aging. 2019 Feb 20;14:399-406. doi: 10.2147/CIA.S192435. eCollection 2019. Clin Interv Aging. 2019. PMID: 30863034 Free PMC article.
-
A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.J Am Acad Dermatol. 2014 Mar;70(3):489-498.e3. doi: 10.1016/j.jaad.2013.10.049. Epub 2014 Jan 9. J Am Acad Dermatol. 2014. PMID: 24411083 Clinical Trial.
Cited by
-
The AR/miR-221/IGF-1 pathway mediates the pathogenesis of androgenetic alopecia.Int J Biol Sci. 2023 Jun 26;19(11):3307-3323. doi: 10.7150/ijbs.80481. eCollection 2023. Int J Biol Sci. 2023. PMID: 37496996 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical